Startups
Promaxo
Oakland, California, United States
Promaxo develops portable low-field magnetic resonance imaging and image-guided intervention technology for point-of-care urology. Its permanent-magnet MRI platform supports prostate biopsy guidance in outpatient settings. The company also develops AI-based tissue characterization and robotic needle guidance; those additional capabilities are described as under development and are not established as commercially cleared by the current company sources. The cleared MRI-guidance system uses pre-existing diagnostic MRI input; its own images are not intended for diagnostic use. The operating business launched in 2016 as Promaxo, Inc.; the current site identifies Promaxo Holdings, Inc., a holding issuer formed in 2024. It is based in Oakland, California. The current website names eight executive and board-secretary leaders, while 2026 securities filings identify additional board directors. Financing history includes MicroPort-backed Series A tranches, a Kineticos-backed Series B-1 tranche, a Huami/Zepp-led financing, direct investment by Fred Moll and an investment by Zynext Ventures. SEC offering targets and grant totals are distinguished from securities actually sold. Promaxo is separate from neuro42 despite sharing founder Amit Vohra.
Founded 2016
Team
 Alek NacevChief Science Officer |
 Alex GonzalezSenior Vice President |
 Amit VohraChief Executive Officer · Board Director |
 Anil DhingraExecutive Vice President |
 Dan McCormickBoard affiliation (published by Kineticos; current holding-board status unconfirmed) |
 Derek HenneckeBoard Director |
 Dushyant ChipalkattyBoard Director |
 Fred MollStrategic Advisor (appointment announced October 2023; current status unverified) |
 Michael BartholomewSecretary of the Board |
 Ram NarayananChief Technology Officer |
 Scott KingChief Product Officer |
 Srirama VenkataramanChief Operating Officer |